Vigonvita Life Sciences Co., Ltd. Class H
HHKEX:263076.55
HKD
-3.45
(-4.31%)
ISIN
CNE1000076N3
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Guang Hui Tian
- Full Time Employees
- 315
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- 8th Floor, Building A, No. 108 Yuxin Road Suzhou JS China 215021
- IPO Date
- Nov 6, 2025
- Website
- vigonvita.cn
- Similar Companies
- Business
- Vigonvita Life Sciences Co., Ltd. is a research-driven biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics in neuropsychiatry, reproductive health, and viral infections. The company advances an integrated pipeline across lead discovery, druggability optimization, preclinical evaluation, and clinical development, with a portfolio that includes multiple small-molecule programs and antiviral candidates targeting urgent unmet medical needs. Its lead assets and late-stage programs concentrate on first-in-class and best-in-class mechanisms, including compounds in Phase II and Phase III clinical development and several preclinical candidates advancing toward human testing. Headquartered in Shanghai, with primary operations in Suzhou and Shanghai, Vigonvita operates an end-to-end platform encompassing innovative drug discovery, translational research, manufacturing readiness, and clinical application. The company emphasizes end-to-end capabilities through its in-house teams and partners, enabling rapid progression from lead identification to clinical trial execution and eventual commercialization. Vigonvita’s geographic footprint and strategic collaborations support its aim to address global markets, with a focus on neuropsychiatric disorders, fertility and reproductive health, and viral infections. Founded in 2013, Vigonvita maintains its headquarters in Shanghai and maintains a significant presence in Suzhou, positioning itself as a regional hub for integrated biopharmaceutical development. The company pursues strategic partnerships, potential licensing arrangements, and collaborations to accelerate development timelines, expand its global reach, and strengthen its pipeline through shared expertise, resources, and capital investment. Vigonvita’s operating model relies on a combination of internally developed drug programs and externally partnered initiatives to optimize value creation across its therapeutic focus areas.